Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment

被引:0
作者
Alexandros A. Drosos
Eleftherios Pelechas
Evripidis Kaltsonoudis
Paraskevi V. Voulgari
机构
[1] University of Ioannina,Rheumatology Clinic, Department of Internal Medicine, Medical School
来源
Current Rheumatology Reports | 2020年 / 22卷
关键词
csDMARDs; bDMARDs; Triple therapy; Cost-effectiveness; Work productivity; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 360 条
[1]  
Burmester GR(2014)Emerging cell and cytokine targets in rheumatoid arthritis Nat Rev Rheumatol 10 77-88
[2]  
Feist E(2019)Current therapeutic options in the treatment of rheumatoid arthritis J Clin Med 8 E938-26
[3]  
Dörner T(2013)Biologic therapy for autoimmune diseases: an update BMC Med 11 88-1003
[4]  
Köhler BM(2016)2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis Arthritis Rheum 68 1-56
[5]  
Günther J(2010)Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 69 995-1600
[6]  
Kaudewitz D(2017)Improvement at any cost? The art and science of choosing treatment strategies for rheumatoid arthritis Ann Intern Med 167 55-2147
[7]  
Lorenz HM(2011)Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis J Rheumatol 38 1593-1368
[8]  
Rosman Z(2016)Best cost-effectiveness and worker productivity with initial triple-DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial Rheumatology (Oxford) 55 2138-15
[9]  
Shoenfeld Y(2019)Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? J Clin Med 8 E1237-341
[10]  
Zandman-Goddard G(2020)Treatment strategies are more important than drugs in the management of rheumatoid arthritis Clin Rheumatol 39 1363-345